Intestinal schistosomiasis vaccine is under clinical development by Quratis and currently in Phase I for Intestinal Schistosomiasis. According to GlobalData, Phase I drugs for Intestinal Schistosomiasis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Intestinal schistosomiasis vaccine LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Intestinal schistosomiasis vaccine overview

Vaccine candidate (SchistoShield) is under development for the prevention of intestinal schistosomiasis. The vaccine candidate consists of full length cDNA of Schistosoma mansoni (Sm)-p80 (calpain) which is cloned with VR1020 virus vector. The vaccine candidate reduces the worm burden. It is administered through intramuscular route.

Quratis overview

Quratis is a pharmaceutical company that is engaged in the production of vaccines for the treatment of tuberculosis. It is headquartered in Seoul, Republic of Korea (South Korea).

For a complete picture of Intestinal schistosomiasis vaccine’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.